Osteoprotegerin (OPG) is a member of the tumor necrosis factor (TNF) receptor family. It has recently been demonstrated that OPG is produced by a variety of tissues, including the cardiovascular system (heart, arteries, veins), lung, kidney, immune tissues, and bone. The OPG-RANKL signaling pathway is strongly related to vascular calcification. We determined the association of this biomarker with subclinical atherosclerosis in systemic lupus erythematous (SLE).
Methods
We measured OPG and markers of subclinical atherosclerosis (coronary artery calcium (CAC), carotid intima-media thickness (cIMT) carotid plaque) in 166 SLE patients (91% female, 64% Caucasian, 31% African American, 5% others, mean age 45 years). Subgroups of patients with different levels of OPG level were compared with respect to average levels of CAC, cIMT, and with respect to presence of carotid plaque. Age was adjusted for using multiple regression.
Results
OPG was highly correlated with age (p < 0.0001). Individuals with higher levels of OPG tended to have higher measures of CAC, cIMT, and more carotid plaque. However, after adjustment for age, these associations, while still positive, were no longer statistically significant.
Conclusion
In our study much of the association observed was due to confounding by age, and after adjusting for age, our findings do not rule out the possibility of a null association.
SimonetWSLaceyDLDunstanCR. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell1997; 89: 309–319.
2.
YunTJChaudharyPMShuGL. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol1998; 161: 6113–6121.
3.
HofbauerLCKhoslaSDunstanCR. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res2000; 15: 2–12.
4.
Collin-OsdobyPRotheLAndersonFNelsonMMaloneyWOsdobyP. Receptor activator of NF-B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem2001; 276: 20659–20672.
5.
BrownerWSLuiLYCummingsSR. Associations of serum osteoprotegrin levels with diabetes, stroke, bone density, fractures and mortality in elderly women. J Clin Endocrinol Metab2001; 86: 631–637.
6.
SchoppetMSattlerAMSchaeferJRHerzumMMaischBHofbauerLC. Increased osteoprotegrin serum levels in men with coronary artery disease. J Clin Endocrinol Metab2003; 88: 1024–1028.
7.
KnudsenSTFossCHPoulsenPLAndersenNHMogensenCERasmussenLM. Increased plasma concentrations of OPG in type 2 diabetic patients with microvascular complications. Eur J Endocrinol2003; 149: 39–42.
8.
SkoumalMKolarzGHaberhauerGWoloszczukWHawaGKlinglerA. Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Rheumatol Int2005; 26: 63–69.
9.
SimoniniGMasiLGianiT. Osteoprotegerin serum levels in Kawasaki disease: An additional potential marker in predicting children with coronary artery involvement. J Rheumatol2005; 32: 2233–2238.
10.
BernsteinCNSargentMLeslieWD. Serum osteoprotegerin is increased in Crohn’s disease: A population-based case control study. Inflamm Bowel Dis2005; 11: 325–330.
11.
KianiANJohnsonKChenC. Urine osteoprotegrin (OPG) and monocyte chemoattractant protein-1 (MCP-1) in lupus nephritis (LN). J Rheumatol2009; 36: 2224–2230.
12.
JonoSIkariYShioiA. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation2002; 106: 1192–1194.
13.
SchoppetMSattlerAMSchaeferJRHerzumMMaischBHofbauerLC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab2003; 88: 1024–1028.
14.
ParkYJShinYJKimWUChoCS. Prediction of subclinical atherosclerosis by serum osteoprotegerin in premenopausal women with systemic lupus erythematous: Correlation of osteoprotegerin with monocyte chemotactic protein-1. Lupus2014; 23: 236–244.
15.
BrelandUMHollanISaatvedtK. Inflammatory markers in patients with coronary artery disease with and without inflammatory rheumatic disease. Rheumatology (Oxford)2010; 49: 1118–1127.
16.
PetriMKianiANPostWChristopher-StineLMagderLS. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis2011; 70: 760–765.
17.
BudoffMJGeorgiouDBrodyA. Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease: A multicenter study. Circulation1996; 93: 898–904.
18.
KoppAFOhnesorgeBBeckerC. Reproducibility and accuracy of coronary calcium measurements with multi-detector row versus electron-beam CT. Radiology2002; 225: 113–119.
19.
BotsMLMulderPGHofmanA. Reproducibility of carotid vessel wall thickness measurements: The Rotterdam study. J Clin Epidemiol1994; 47: 921–930.
20.
SmildeTJWollersheimHVan LangenH. Reproducibility of ultrasonographic measurements of different carotid and femoral artery segments in healthy subjects and in patients with increased intima-media thickness. Clin Sci1997; 93: 317–324.
21.
RomanMJCrowMKLockshinMD. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum2007; 56: 3412–3419.
22.
ThompsonTSutton-TyrrellKWildmanRP. Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum2008; 58: 835–842.
23.
UelandTAukrustPDahlCPHusebyeT. Osteoprotegrin levels predict mortality in patients with symptomatic aortic stenosis. J Intern Med2011; 270: 452–460.
24.
KwokSKShinYJKimHJ. Circulating osteoprotegerin levels are elevated and correlated with antiphospholipid antibodies in patients with systemic lupus erythematosus. Lupus2009; 18: 133–138.
25.
SzulcPHofbauerLCHeufelderAERothSDelmasPD. Osteoprotegerin serum levels in men: Correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab2001; 86: 3162–3165.
26.
KhoslaSArrighiHMMeltonLJ3rd. Correlates of osteoprotegerin levels in women and men. Osteoporos Int2002; 13: 394–399.
27.
Van CampenhoutAGolledgeJ. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis2009; 204: 321–329.
28.
SandbergWJYndestadAOieE. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: Possible role in plaque destabilization. Arterioscler Thromb Vasc Biol2006; 26: 857–863.
29.
BeyazalMSErdoğanTDevrimselG. Relationship of osteoprotegerin to pulse wave velocity and carotid intima-media thickness in rheumatoid arthritis patients. Z Rheumatol2016; 75: 723–728.
30.
KimSMLeeJRyuOH. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin Endocrinol2005; 63: 594–598.
31.
SummeyBTYosipovitchG. Glucocorticoid induced bone loss in dermatologic patients: An update. Arch Dermatol2006; 142: 82–90.
